Exendin-4 to treat nonalcoholic steatohepatitis and nonalcoholic fatty liver disease
View Patent ↗The present invention relates generally to the novel use of incretin compounds (ICs) and amylinomimetic compounds to treat, prevent, or ameliorate a variety of metabolic conditions or diseases.
1. A method for treating nonalcoholic steatohepatitis in a human in need thereof comprising subcutaneously administering to the human a therapeutically effective amount of exendin-4 to treat the nonalcoholic steatohepatitis in the human.
2. The method of claim 1 , further comprising administering a therapeutically effective amount of a dipeptidyl peptidase-IV inhibitor, metformin, a sulfonylurea, or a combination of two or more thereof.
3. A method for treating nonalcoholic steatohepatitis in a subject in need thereof comprising administering to the subject a therapeutically effective amount of exendin-4 to treat the nonalcoholic steatohepatitis in the subject.
4. The method of claim 3 , wherein the therapeutically effective amount is an amount that maintains an average plasma concentration of exendin-4 of at least 10 pg/ml for at least 12 hours.
5. The method of claim 3 , wherein the exendin-4 is parenterally administered to the subject.
6. The method of claim 3 , wherein the subject is a human.
7. The method of claim 3 , wherein the exendin-4 is administered to the subject by subcutaneous injection.
8. The method of claim 3 , further comprising administering a therapeutically effective amount of a dipeptidyl peptidase-IV inhibitor, metformin, a sulfonylurea, or a combination of two or more thereof.
9. A method for treating nonalcoholic fatty liver disease in a subject in need thereof comprising administering to the subject a therapeutically effective amount of exendin-4 to treat the nonalcoholic fatty liver disease in the subject.
10. The method of claim 9 , wherein the therapeutically effective amount is an amount that maintains an average plasma concentration of exendin-4 of at least 10 pg/ml for at least 12 hours.
11. The method of claim 9 , wherein the exendin-4 is parenterally administered to the subject.
12. The method of claim 9 , wherein the subject is a human.
13. The method of claim 9 , wherein the exendin-4 is administered to the subject by subcutaneous injection.
14. The method of claim 9 , further comprising administering a therapeutically effective amount of a dipeptidyl peptidase-IV inhibitor, metformin, a sulfonylurea, or a combination of two or more thereof.
15. A method for treating nonalcoholic fatty liver disease in a human in need thereof comprising subcutaneously administering to the human a therapeutically effective amount of exendin-4 to treat the nonalcoholic fatty liver disease in the human.
16. The method of claim 15 , further comprising administering a therapeutically effective amount of a dipeptidyl peptidase-IV inhibitor, metformin, a sulfonylurea, or a combination of two or more thereof.